{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:37:27Z","timestamp":1789663047273,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00198-025-07706-8","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:35:48Z","timestamp":1760348148000},"page":"2273-2285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bridging the knowledge gap in rare bone disorders: insights from the APCO Asia-Pacific Rare Bone Disorders Engagement (ASPIRE) survey"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-8443","authenticated-orcid":false,"given":"Manju","family":"Chandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Kassim","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia","family":"Newell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick","family":"Clifton-Bligh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig F.","family":"Munns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Trombetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay Kumar","family":"Bhadada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Ebeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrish","family":"Mithal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria\u00a0Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"7706_CR1","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/ajmg.a.63132","volume":"191","author":"S Unger","year":"2023","unstructured":"Unger S, Ferreira CR, Mortier GR (2023) Nosology of genetic skeletal disorders: 2023 revision. Am J Med Genet A 191:1164\u20131209. https:\/\/doi.org\/10.1002\/ajmg.a.63132","journal-title":"Am J Med Genet A"},{"key":"7706_CR2","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s00198-015-3188-9","volume":"26","author":"L Masi","year":"2015","unstructured":"Masi L, Agnusdei D, Bilezikian J et al (2015) Taxonomy of rare genetic metabolic bone disorders. Osteoporos Int 26:2529\u20132558. https:\/\/doi.org\/10.1007\/s00198-015-3188-9","journal-title":"Osteoporos Int"},{"key":"7706_CR3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00198-023-06791-x","volume":"34","author":"M Chandran","year":"2023","unstructured":"Chandran M, Alves I, Carpenter T et al (2023) Improving care pathways for people living with rare bone diseases (RBDs): outcomes from the first RBD summit. Osteoporos Int 34:1301\u20131310. https:\/\/doi.org\/10.1007\/s00198-023-06791-x","journal-title":"Osteoporos Int"},{"key":"7706_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/children9050710","volume":"9","author":"M Sandquist","year":"2022","unstructured":"Sandquist M, Davenport T, Monaco J, Lyon ME (2022) The transition to adulthood for youth living with rare diseases. Children 9:710. https:\/\/doi.org\/10.3390\/children9050710","journal-title":"Children"},{"key":"7706_CR5","doi-asserted-by":"publisher","DOI":"10.20517\/rdodj.2023.42","volume":"3","author":"R Jain","year":"2024","unstructured":"Jain R, Wang CM, Foster L et al (2024) Paradox of possibilities: the rare landscape in the Asia Pacific region. Rare Disease and Orphan Drugs Journal 3:N\/A-N\/A. https:\/\/doi.org\/10.20517\/rdodj.2023.42","journal-title":"Rare Disease and Orphan Drugs Journal"},{"key":"7706_CR6","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00198-020-05495-w","volume":"31","author":"M Chandran","year":"2020","unstructured":"Chandran M, Bhadada SK, Ebeling PR et al (2020) IQ driving QI: the Asia Pacific Consortium on Osteoporosis (APCO): an innovative and collaborative initiative to improve osteoporosis care in the Asia Pacific. Osteoporos Int 31:2077\u20132081. https:\/\/doi.org\/10.1007\/s00198-020-05495-w","journal-title":"Osteoporos Int"},{"key":"7706_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001344","volume":"6","author":"R Talarico","year":"2020","unstructured":"Talarico R, Marinello D, Bombardieri S et al (2020) Clinical practice guidelines adherence, knowledge and awareness in rare and complex connective tissue diseases across Europe: results from the first ERN reconnet survey. RMD Open 6:0. https:\/\/doi.org\/10.1136\/rmdopen-2020-001344","journal-title":"RMD Open"},{"key":"7706_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jposna.2024.100057","volume":"7","author":"LL Tosi","year":"2024","unstructured":"Tosi LL (2024) Rare genetic skeletal disorders: evolving terminology, therapies, education and advocacy. J Pediatr Soc North Am 7:100057. https:\/\/doi.org\/10.1016\/j.jposna.2024.100057","journal-title":"J Pediatr Soc North Am"},{"key":"7706_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13023-023-02667-9","volume":"18","author":"M Gittus","year":"2023","unstructured":"Gittus M, Chong J, Sutton A et al (2023) Barriers and facilitators to the implementation of guidelines in rare diseases: a systematic review. Orphanet J Rare Dis 18:140. https:\/\/doi.org\/10.1186\/s13023-023-02667-9","journal-title":"Orphanet J Rare Dis"},{"key":"7706_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10744","volume":"7","author":"CF Munns","year":"2023","unstructured":"Munns CF, Yoo H-W, Jalaludin MY et al (2023) Asia-Pacific consensus recommendations on X-linked hypophosphatemia: diagnosis, multidisciplinary management, and transition from pediatric to adult care. JBMR Plus 7:e10744. https:\/\/doi.org\/10.1002\/jbm4.10744","journal-title":"JBMR Plus"},{"key":"7706_CR11","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41581-024-00926-x","volume":"21","author":"D Haffner","year":"2025","unstructured":"Haffner D, Emma F, Seefried L et al (2025) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 21:330\u2013354. https:\/\/doi.org\/10.1038\/s41581-024-00926-x","journal-title":"Nat Rev Nephrol"},{"key":"7706_CR12","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1210\/clinem\/dgaf093","volume":"110","author":"DS Ali","year":"2025","unstructured":"Ali DS, Carpenter TO, Imel EA et al (2025) X-linked hypophosphatemia management in children: an international working group clinical practice guideline. J Clin Endocrinol Metab 110:2055\u20132070. https:\/\/doi.org\/10.1210\/clinem\/dgaf093","journal-title":"J Clin Endocrinol Metab"},{"key":"7706_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","volume":"14","author":"MK Javaid","year":"2019","unstructured":"Javaid MK, Boyce A, Appelman-Dijkstra N et al (2019) Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium. Orphanet J Rare Dis 14:139. https:\/\/doi.org\/10.1186\/s13023-019-1102-9","journal-title":"Orphanet J Rare Dis"},{"key":"7706_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13023-018-0905-4","volume":"13","author":"B Mueller","year":"2018","unstructured":"Mueller B, Engelbert R, Baratta-Ziska F et al (2018) Consensus statement on physical rehabilitation in children and adolescents with osteogenesis imperfecta. Orphanet J Rare Dis 13:158. https:\/\/doi.org\/10.1186\/s13023-018-0905-4","journal-title":"Orphanet J Rare Dis"},{"key":"7706_CR15","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1080\/17453674.2021.1941628","volume":"92","author":"RJ Sakkers","year":"2021","unstructured":"Sakkers RJ, Montpetit K, Tsimicalis A et al (2021) A roadmap to surgery in osteogenesis imperfecta: results of an international collaboration of patient organizations and interdisciplinary care teams. Acta Orthop 92:608\u2013614. https:\/\/doi.org\/10.1080\/17453674.2021.1941628","journal-title":"Acta Orthop"},{"key":"7706_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1383681","volume":"15","author":"GI Baroncelli","year":"2024","unstructured":"Baroncelli GI, Comberiati P, Aversa T (2024) Diagnosis, treatment, and management of rickets: a position statement from the Bone and Mineral Metabolism Group of the Italian Society of Pediatric Endocrinology and Diabetology. Front Endocrinol (Lausanne) 15:1383681. https:\/\/doi.org\/10.3389\/fendo.2024.1383681","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7706_CR17","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","volume":"18","author":"A Trombetti","year":"2022","unstructured":"Trombetti A, Al-Daghri N, Brandi ML et al (2022) Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. Nat Rev Endocrinol 18:366\u2013384. https:\/\/doi.org\/10.1038\/s41574-022-00662-x","journal-title":"Nat Rev Endocrinol"},{"key":"7706_CR18","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf170","author":"AA Khan","year":"2025","unstructured":"Khan AA, Ali DS, Appelman-Dijkstra NM (2025) X-linked hypophosphatemia management in adults: an international working group clinical practice guideline. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaf170","journal-title":"J Clin Endocrinol Metab"},{"key":"7706_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-023-06843-2","volume":"35","author":"E Rush","year":"2024","unstructured":"Rush E, Brandi ML, Khan A et al (2024) Proposed diagnostic criteria for the diagnosis of hypophosphatasia in children and adolescents: results from the HPP International Working Group. Osteoporos Int 35:1\u201310. https:\/\/doi.org\/10.1007\/s00198-023-06843-2","journal-title":"Osteoporos Int"},{"key":"7706_CR20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00198-023-06844-1","volume":"35","author":"AA Khan","year":"2024","unstructured":"Khan AA, Brandi ML, Rush ET et al (2024) Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults. Osteoporos Int 35:431\u2013438. https:\/\/doi.org\/10.1007\/s00198-023-06844-1","journal-title":"Osteoporos Int"},{"key":"7706_CR21","unstructured":"APCO Clinical Case Discussion Platform (CCDP). In: APCO. https:\/\/apcobonehealth.org\/clinical-case-discussion-platform-ccdp\/. Accessed 6 Jul 2025"},{"key":"7706_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.652358","volume":"8","author":"KM Stepien","year":"2021","unstructured":"Stepien KM, Kie\u0107-Wilk B, Lampe C et al (2021) Challenges in transition from childhood to adulthood care in rare metabolic diseases: results from the first multi-center European survey. Front Med Lausanne 8:652358. https:\/\/doi.org\/10.3389\/fmed.2021.652358","journal-title":"Front Med Lausanne"},{"key":"7706_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00223-025-01382-w","volume":"116","author":"C Grasemann","year":"2025","unstructured":"Grasemann C, Wernsmann J, Appelman-Dijkstra NM et al (2025) Transition care for young persons with rare bone mineral conditions: a consensus recommendation from the ECTS rare bone disease action group. Calcif Tissue Int 116:73. https:\/\/doi.org\/10.1007\/s00223-025-01382-w","journal-title":"Calcif Tissue Int"},{"key":"7706_CR24","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11914-020-00595-2","volume":"18","author":"LL Tosi","year":"2020","unstructured":"Tosi LL, Rajah EN, Stewart MH et al (2020) The rare bone disease teleecho program: leveraging telehealth to improve rare bone disease care. Curr Osteoporos Rep 18:344\u2013349. https:\/\/doi.org\/10.1007\/s11914-020-00595-2","journal-title":"Curr Osteoporos Rep"},{"key":"7706_CR25","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s00223-024-01256-7","volume":"115","author":"AL Priego Zurita","year":"2024","unstructured":"Priego Zurita AL, Boarini M, Casareto L et al (2024) The role of the European Reference Network for Rare Bone Diseases (ERN BOND) and European Registries for Rare Bone and Mineral Conditions (EuRR-Bone) in the governance of the management of rare bone and mineral diseases. Calcif Tissue Int 115:498\u2013506. https:\/\/doi.org\/10.1007\/s00223-024-01256-7","journal-title":"Calcif Tissue Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07706-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07706-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07706-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T12:32:11Z","timestamp":1763382731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07706-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["7706"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07706-8","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MC has received honoraria for speaking engagements from Kyowa Kirin and Amgen and travel grants from Amgen. She is Chairperson of the Asia Pacific Consortium on Osteoporosis (APCO).\nMKJ has received paid consultancy or sponsorship for external talks from Amgen, UCB, Sanofi, Kyowa Kirin, Nanox-AI, Naitive Technologies, Thornton Ross, and Theramex. His Institution\u2014NDORMS, University of Oxford\u2014has received unrestricted research grants from UCB, Amgen, and Kyowa Kirin.TN works for inVIVO Academy.SK is Project Manager for APCO.RCB has had speaker honoraria and\/or advisory boards for Amgen, Ipsen, Lilly, Specialized Therapeutics, and Kyowa Kirin.CM has received research funding from Amgen and Kyowa Kirin, consultancy fees from Kyowa Kirin and Amgen, and speaker fees from Kyowa Kirin.AT has received paid consultancy from Kyowa Kirin, Ascendis pharma, Alexion, and Pharmacosmos.SKB is an Executive Committee Member of APCO.PRE has had research funding from Alexion and honoraria from Alexion and Kyowa Kirin. He is an Executive Committee Member of APCO.AM is a Scientific Advisory Member of APCO.M-LB has received honoraria from Calcilytix and Kyowa Kirin, received grants and\/or served as a speaker for Alexion and Kyowa Kirin, and is a consultant for Alexion, Amolyt, Calcilytix, and Kyowa Kirin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}